Company
Columbus, OS
Every investor coverage indicates participated in a round Ohio State University raised.
Companies Ohio State University acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr William T Abraham | National Co-lead Principal Investigator | GBS Ventures (25 Sep 2008), GBS Ventures (18 Sep 2008) |
| Dr William T Abraham | Division Director of Cardiovascular Medicine | GBS Ventures (12 Sep 2008), GBS Ventures (22 Feb 2007) |
Stories naming Ohio State University. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Medical device maker Sunshine Heart reports its first two American C-Pulse patients cleared three-month follow-ups, booked initial reimbursement revenue from an Ohio trial site, and outlines coming CE Mark and FDA steps.
Sunshine Heart won complete US regulator clearance to run its first American trial of the C-Pulse heart device, having satisfied conditions attached to September's conditional clearance; enrolment of trial participants was anticipated that year.
Sunshine Heart says the US FDA approved a reimbursement category for its C-Pulse heart assist trial, opening Medicare reimbursement; it retained Quorum Consulting and expects patient enrollment at six US institutions in late 2008.
US regulators have conditionally cleared Sunshine Heart to begin its first American trial of the C-Pulse heart assist device in moderate heart failure patients, with enrollment at six institutions.
Sunshine Heart says the US regulator has conditionally cleared its first American trial of the C-Pulse heart assist device, with about twenty patients to enrol across six US hospitals from late 2008.
Two American heart failure specialists have agreed to serve as co-principal investigators for Sunshine Heart's C-Pulse feasibility trial, which the company says adds credibility as it prepares a wider US study in 2007.